GT Biopharma Inc (GTBP)
3.01
+0.05
(+1.69%)
USD |
NASDAQ |
Jun 25, 16:00
3.11
+0.10
(+3.32%)
After-Hours: 20:00
GT Biopharma Research and Development Expense (TTM): 5.593M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 5.593M |
| December 31, 2023 | 6.466M |
| September 30, 2023 | 7.951M |
| June 30, 2023 | 9.33M |
| March 31, 2023 | 8.374M |
| December 31, 2022 | 8.811M |
| September 30, 2022 | 12.27M |
| June 30, 2022 | 10.54M |
| March 31, 2022 | 10.04M |
| December 31, 2021 | 9.591M |
| September 30, 2021 | 3.52M |
| June 30, 2021 | 2.428M |
| March 31, 2021 | 1.801M |
| December 31, 2020 | 0.485M |
| September 30, 2020 | 0.26M |
| June 30, 2020 | 1.015M |
| March 31, 2020 | 1.157M |
| December 31, 2019 | 1.667M |
| September 30, 2019 | 2.891M |
| June 30, 2019 | 3.331M |
| March 31, 2019 | 6.428M |
| December 31, 2018 | 9.067M |
| September 30, 2018 | 7.992M |
| June 30, 2018 | 7.407M |
| March 31, 2018 | 4.397M |
| Date | Value |
|---|---|
| December 31, 2017 | 1.068M |
| September 30, 2017 | 1.161M |
| June 30, 2017 | 0.885M |
| March 31, 2017 | 0.894M |
| December 31, 2016 | 0.975M |
| September 30, 2016 | 1.25M |
| June 30, 2016 | 1.225M |
| March 31, 2016 | 0.975M |
| December 31, 2015 | 1.00M |
| September 30, 2015 | 0.475M |
| June 30, 2015 | 0.25M |
| March 31, 2015 | 0.25M |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 0.00 |
| September 30, 2012 | -0.032M |
| June 30, 2012 | -0.032M |
| March 31, 2012 | -0.004M |
| December 31, 2011 | 0.017M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
0.26M
Minimum
Sep 2020
12.27M
Maximum
Sep 2022
5.376M
Average
4.556M
Median
Research and Development Expense (TTM) Benchmarks
| Cutera Inc | 19.94M |
| Oragenics Inc | 14.48M |
| Outlook Therapeutics Inc | 34.08M |
| 180 Life Sciences Corp | 2.525M |
| Scorpius Holdings Inc | 18.30M |